• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by ADC Therapeutics SA

    8/14/25 4:15:34 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADCT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    ADC Therapeutics SA

    (Name of Issuer)


    Common Shares, par value CHF 0.08 per share

    (Title of Class of Securities)


    H0036K147

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    H0036K147


    1Names of Reporting Persons

    Redmile Group, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    15,666,731.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    15,666,731.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    15,666,731.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    14.0 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  Redmile Group, LLC's beneficial ownership of the Issuer's common shares ("Common Stock") is comprised of 15,666,731 shares of Common Stock owned by certain private investment vehicles managed by Redmile Group, LLC (collective, the "Redmile Clients"), including RedCo II Master Fund, L.P. ("RedCo II"), which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of the Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Percentage based on the sum of (i) 99,178,286 shares of Common Stock outstanding as of May 1, 2025, as reported by the Issuer in its Form 10-Q for the quarterly period ended March 31, 2025 filed with the Securities and Exchange Commission (the "SEC") on May 14, 2025 (the "Form 10-Q"); plus (ii) 13,031,161 shares of Common Stock issued by the Issuer in a private placement as of June 16, 2025, as reported by the Issuer in its Form 8-K filed with the SEC on June 12, 2025 (the "Form 8-K").


    SCHEDULE 13G

    CUSIP No.
    H0036K147


    1Names of Reporting Persons

    Jeremy C. Green
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    15,666,731.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    15,666,731.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    15,666,731.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    14.0 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  Jeremy C. Green's beneficial ownership of the Common Stock is comprised of 15,666,731 shares of Common Stock owned by the Redmile Clients, including RedCo II, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of the Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Percentage based on the sum of (i) 99,178,286 shares of Common Stock outstanding as of May 1, 2025, as reported by the Issuer in the Form 10-Q; plus (ii) 13,031,161 shares of Common Stock issued by the Issuer in a private placement as of June 16, 2025, as reported by the Issuer in the Form 8-K.


    SCHEDULE 13G

    CUSIP No.
    H0036K147


    1Names of Reporting Persons

    RedCo II Master Fund, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    13,145,712.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    13,145,712.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    13,145,712.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    11.7 %
    12Type of Reporting Person (See Instructions)

    PN, FI

    Comment for Type of Reporting Person:  Percentage based on the sum of (i) 99,178,286 shares of Common Stock outstanding as of May 1, 2025, as reported by the Issuer in the Form 10-Q; plus (ii) 13,031,161 shares of Common Stock issued by the Issuer in a private placement as of June 16, 2025, as reported by the Issuer in the Form 8-K.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ADC Therapeutics SA
    (b)Address of issuer's principal executive offices:

    Biopole, Route de la Corniche 3B, 1066 Epalinges, Switzerland
    Item 2. 
    (a)Name of person filing:

    Redmile Group, LLC Jeremy C. Green RedCo II Master Fund, L.P.
    (b)Address or principal business office or, if none, residence:

    Redmile Group, LLC One Letterman Drive Building D, Suite D3-300 The Presidio of San Francisco San Francisco, California 94129 Jeremy C. Green c/o Redmile Group, LLC (NY Office) 45 W. 27th Street, Floor 11 New York, NY 10001 RedCo II Master Fund, L.P. c/o Redmile Group, LLC One Letterman Drive Building D, Suite D3-300 The Presidio of San Francisco San Francisco, California 94129
    (c)Citizenship:

    Redmile Group, LLC: Delaware Jeremy C. Green: United Kingdom RedCo II Master Fund, L.P.: Cayman Islands
    (d)Title of class of securities:

    Common Shares, par value CHF 0.08 per share
    (e)CUSIP No.:

    H0036K147
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Redmile Group, LLC - 15,666,731 (1) Jeremy C. Green - 15,666,731 (1) RedCo II Master Fund, L.P. - 13,145,712 (2)
    (b)Percent of class:

    Redmile Group, LLC - 14.0% (3) Jeremy C. Green - 14.0% (3) RedCo II Master Fund, L.P. - 11.7% (3)
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Redmile Group, LLC - 0 Jeremy C. Green - 0 RedCo II Master Fund, L.P. - 0

     (ii) Shared power to vote or to direct the vote:

    Redmile Group, LLC - 15,666,731 (1) Jeremy C. Green - 15,666,731 (1) RedCo II Master Fund, L.P. - 13,145,712 (2)

     (iii) Sole power to dispose or to direct the disposition of:

    Redmile Group, LLC - 0 Jeremy C. Green - 0 RedCo II Master Fund, L.P. - 0

     (iv) Shared power to dispose or to direct the disposition of:

    Redmile Group, LLC - 15,666,731 (1) Jeremy C. Green - 15,666,731 (1) RedCo II Master Fund, L.P. - 13,145,712 (2) (1) The shares of the Issuer's Common Stock reported herein are held by certain Redmile Clients, including RedCo II, for which Redmile Group, LLC is the investment manager/adviser and, in such capacity, exercises voting and investment power over all of the shares of Common Stock held by the Redmile Clients and may be deemed to be the beneficial owner of these shares. Jeremy C. Green serves as the principal of Redmile Group, LLC and also may be deemed to be the beneficial owner of these shares. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. The shares of Common Stock beneficially owned by Redmile Group, LLC and Mr. Green exclude 23,897,532 shares issuable upon the exercise of the pre-funded warrants held by certain Redmile Clients, including RedCo II, as such warrants include a provision that a holder is prohibited from exercising such warrants to the extent that, upon such exercise, the shares of Common Stock then beneficially owned by the holder and its affiliates and any other person or entity with whom the exercising holder's beneficial ownership would be aggregated for purposes of Section 13(d) under the Securities Exchange Act of 1934, as amended (the "Act"), would exceed 9.99% of the total number of shares of Common Stock outstanding immediately after giving effect to such exercise. (2) The shares of Common Stock beneficially owned by RedCo II exclude 18,599,071 shares issuable upon the exercise of the pre-funded warrants held by RedCo II, as such warrants include a provision that a holder is prohibited from exercising such warrants to the extent that, upon such exercise, the shares of Common Stock then beneficially owned by the holder and its affiliates and any other person or entity with whom the exercising holder's beneficial ownership would be aggregated for purposes of Section 13(d) under the Act, would exceed 9.99% of the total number of shares of Common Stock outstanding immediately after giving effect to such exercise. (3) Percentage based on the sum of (i) 99,178,286 shares of Common Stock outstanding as of May 1, 2025, as reported by the Issuer in the Form 10-Q; plus (ii) 13,031,161 shares of Common Stock issued by the Issuer in a private placement as of June 16, 2025, as reported by the Issuer in the Form 8-K.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See the response to Item 4.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Redmile Group, LLC
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Managing Member
    Date:08/14/2025
     
    Jeremy C. Green
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Jeremy C. Green
    Date:08/14/2025
     
    RedCo II Master Fund, L.P.
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Managing Member of RedCo II (GP), LLC, general partner of RedCo II Master Fund, L.P.
    Date:08/14/2025
    Get the next $ADCT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADCT

    DatePrice TargetRatingAnalyst
    11/8/2024$6.00Overweight
    Stephens
    5/30/2024Overweight
    Cantor Fitzgerald
    3/28/2024$11.00Buy
    Guggenheim
    8/10/2023Underweight → Neutral
    JP Morgan
    4/24/2023$7.00 → $2.00Neutral → Underperform
    BofA Securities
    12/6/2022$12.00Overweight
    CapitalOne
    11/9/2022$14.00 → $7.00Buy → Neutral
    BofA Securities
    9/21/2022$5.00Overweight
    JP Morgan
    More analyst ratings

    $ADCT
    SEC Filings

    View All

    ADC Therapeutics SA filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ADC Therapeutics SA (0001771910) (Filer)

    1/12/26 8:37:42 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADC Therapeutics SA filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ADC Therapeutics SA (0001771910) (Filer)

    1/8/26 5:04:29 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by ADC Therapeutics SA

    EFFECT - ADC Therapeutics SA (0001771910) (Filer)

    12/15/25 12:15:22 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stephens initiated coverage on ADC Therapeutics with a new price target

    Stephens initiated coverage of ADC Therapeutics with a rating of Overweight and set a new price target of $6.00

    11/8/24 7:32:36 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on ADC Therapeutics

    Cantor Fitzgerald initiated coverage of ADC Therapeutics with a rating of Overweight

    5/30/24 7:26:04 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on ADC Therapeutics with a new price target

    Guggenheim initiated coverage of ADC Therapeutics with a rating of Buy and set a new price target of $11.00

    3/28/24 7:31:32 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

    LAUSANNE, Switzerland, Feb. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 308,000 of the Company's common shares to seven new employees on February 2, 2026 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to mo

    2/2/26 4:05:00 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium

    Issued on behalf of Oncolytics Biotech Inc. Equity-Insider.com News Commentary  VANCOUVER, BC, Jan. 30, 2026 /PRNewswire/ -- The oncology sector is undergoing a massive capital rotation driven by over 50 FDA approvals in 2025, with 20 arriving in Q4 alone[1]. This regulatory surge signals deep institutional confidence in late-stage platforms capable of commercial conversion. The trend accelerated in January 2026 as Big Pharma intensified its race to acquire assets ahead of a $170 billion patent cliff[2]. Acquirers are now bypassing early-stage speculation to secure validated Phase 3 data and manufacturing infrastructure. This structural shift has directed institutional focus toward Oncolytic

    1/30/26 10:36:00 AM ET
    $ABBV
    $ADCT
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates

    Preliminary unaudited fourth quarter and full year 2025 net product revenue of approximately $22M and $73M respectively; cash and cash equivalents of approximately $261M as of December 31, 2025, provide expected cash runway at least to 2028 Anticipated near-term catalysts include LOTIS-7 complete enrollment in first half of 2026 and LOTIS-5 Phase 3 topline data in second quarter 2026 Additional anticipated catalysts include full LOTIS-5 and LOTIS-7 results by end of 2026, with potential compendia inclusions in first half of 2027 and LOTIS-5 regulatory approvals to follow LAUSANNE, Switzerland, Jan. 8, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and

    1/8/26 4:05:00 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Mallik Ameet covered exercise/tax liability with 233,146 shares, decreasing direct ownership by 15% to 1,319,101 units (SEC Form 4)

    4 - ADC Therapeutics SA (0001771910) (Issuer)

    12/9/25 5:10:09 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Zaki Mohamed covered exercise/tax liability with 41,068 shares, decreasing direct ownership by 9% to 421,820 units (SEC Form 4)

    4 - ADC Therapeutics SA (0001771910) (Issuer)

    12/9/25 5:09:56 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Kallebo Lisa Michelle covered exercise/tax liability with 7,140 shares, decreasing direct ownership by 9% to 70,757 units (SEC Form 4)

    4 - ADC Therapeutics SA (0001771910) (Issuer)

    12/9/25 5:09:44 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Redmile Group, Llc bought $609,000 worth of shares (200,000 units at $3.04) (SEC Form 4)

    4 - ADC Therapeutics SA (0001771910) (Issuer)

    12/13/24 9:00:14 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Redmile Group, Llc bought $2,248,000 worth of shares (800,000 units at $2.81) (SEC Form 4)

    4 - ADC Therapeutics SA (0001771910) (Issuer)

    7/3/24 8:00:13 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-5) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

    10/13/22 1:04:01 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-4) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

    10/13/22 1:03:14 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (ORIG-1) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 04/23/2021. Application Category: BLA, Application Number: 761196, Application Classification:

    4/23/21 1:46:03 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

    SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

    11/14/24 9:00:57 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

    SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

    11/13/24 8:58:56 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

    SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

    11/13/24 8:30:55 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    Leadership Updates

    Live Leadership Updates

    View All

    The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

    6/26/25 11:44:00 AM ET
    $ADCT
    $CTOR
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

    £90m ($114m) series A co-led by new leading life science investors Novo Holdings and AbingworthAdditional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova PartnersFunds will be used to build out Myricx Bio's proprietary N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform and advance its pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigensCompany to establish laboratory operations in London's biotech hub, and expand its management and R&D teamsMichael Bauer from Novo Holdings and Lucille Conroy from Abi

    7/8/24 2:00:00 AM ET
    $ADCT
    $CG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

    LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. "We are pleased to be joining the Russell 2000® Index," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "This is a significant benchmark validating the focused execution of our corporate and capital allocation strategy and our progress toward multiple upcoming expected milestones throughout our hematology and solid tumor portfolios." Th

    6/27/24 7:15:00 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADCT
    Financials

    Live finance-specific insights

    View All

    ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

    ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated an 89.8% ORR and 77.6% CR across the 49 efficacy-evaluable patients with a minimum of 6 months of follow-up Combination continues to be generally well-tolerated with a manageable safety profile LOTIS-7 trial is on track for complete patient enrollment in 1H 2026; plan to share full data at a medical meeting and submit for publication by end of 2026 Company to host conference call today at 8:00 a.m. EST LAUSANNE, Switzerland, Dec. 3, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the LOTIS-7 Phas

    12/3/25 7:30:00 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial

    Company to host corporate webcast to share updated data on December 3, 2025 LAUSANNE, Switzerland, Dec. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Wednesday, December 3, 2025, at 8:00 a.m. EST to provide an update on the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

    12/2/25 4:05:00 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update

    Continued progress across LOTIS-7 with updated data anticipated in 2025 and LOTIS-5 with topline data expected in 1H 2026 Updated data from Phase 2 IIT of ZYNLONTA® plus rituximab in patients with r/r follicular lymphoma presented at the 22nd International Workshop on Non-Hodgkin Lymphoma Recent financing supports expansion of ZYNLONTA in anticipation of 2L+ DLBCL launch with strengthened balance sheet relative to previously disclosed cash runway into 2028 LAUSANNE, Switzerland, Nov. 10, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the third quarter ende

    11/10/25 7:30:00 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care